AR and posterior cortical atrophy: To date, AR-V7 is the type of AR-V most frequently detected in CRPC.545,546 AR-V7 was found to contribute to resistance to enzalutamide and abiraterone in PCa patients.547 In addition, other studies have demonstrated that other AR-Vs such as AR-V1, AR-V3, AR-V9, and ARv567es confer anti-AR drug resistance.548,549 Thus, further development of AR-V-targeted drugs such as AR-DBD or AR-NTD is required,550,551 since these domains are shared between full-length AR, LBD-mutant AR, and AR-Vs.